21 – 30 of 93
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer : the Danish cohort of BIG 1-98
(
- Contribution to journal › Article
-
Mark
Tumor tissue protein signatures reflect histological grade of breast cancer
2017) In PLoS ONE(
- Contribution to journal › Article
-
Mark
AIB1 is a new putative prognostic biomarker in the luminal A and B-like (HER2-negative) classification of invasive lobular carcinoma
(
- Contribution to conference › Abstract
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffin-blocks for estrogen receptor evaluation
(
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer.
(
- Contribution to journal › Article
-
Mark
St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
(
- Contribution to journal › Article
- 2015
-
Mark
Reply from Authors re: Bas W.G. van Rhijn, Mark A. Behrendt, Kees Hendricksen, Theo H. van der Kwast. Toward Optimal Prediction of Prognosis in T1 Urothelial Carcinoma of the Bladder. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.03.030.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing.
(
- Contribution to journal › Article
-
Mark
Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.
(
- Contribution to journal › Article